Quality of life · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Social and occupational functioning · participants with long‐term antidepressants for depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful discontinuation rate · participants with depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of dementia compared with usual care/placebo (high certainty).
1 finding from 1 review
Incidence of MCI · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of MCI compared with usual care/placebo (moderate certainty).
1 finding from 1 review
Cognitive decline · Older people living in the community
3 findings from 1 review
no estimate extracted
3 studies · 4617 participants
High
no estimate extracted
6 studies · 8697 participants
Moderate
no estimate extracted
2 studies · 1554 participants
Very low
All‐cause mortality · Older people living in the community
Multi‐domain interventions showed no clear difference in mortality compared with usual care/placebo (high certainty).
1 finding from 1 review
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: IMV or death (≥ 7 WHO scale) · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in clinical progression: need for IMV or death (WHO ≥ 7) compared with usual care alone (moderate certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in hospital discharge alive by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom (100% reduction in seizure frequency) compared with usual care (very low certainty).
1 finding from 1 review
Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review